Quick one - I was poking around [ClinicalTrials.gov](http://ClinicalTrials.gov) and noticed VOR’s Phase 3 study NCT05306574 just flipped to Terminated.
A couple details that made me pause:
* Status: Active, not recruiting → Terminated
* “Why study stopped”: Business decision
* Enrollment: 350 → 91 (down 259, \~-74%)
This is a bit odd alongside the general “telitacicept had good China data” narrative floating around, so I’m trying to interpret what’s most likely here.
For folks who’ve watched these: when you see “business decision” + a big enrollment cut on a Phase 3 termination, do you usually read that as (a) runway / reprioritization / ops feasibility… or (b) sometimes a polite way of saying the risk/reward isn’t there?
(Info only / not investment advice.)